11:27 AM EDT, 03/27/2024 (MT Newswires) -- Zai Lab's ( ZLAB ) and Novocure ( NVCR ) said Wednesday that the phase 3 METIS trial met its primary endpoint, showing that Tumor Treating Field therapy with supportive care significantly prolongs the time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

Patients on TTFields with supportive care had a median intracranial progression time of 21.9 months, compared to 11.3 months for those on supportive care alone, the companies said.

The trial involved 298 adult NSCLC patients with 1-10 brain metastases post-stereotactic radiosurgery. TTFields therapy lasted around 16 weeks on average, with 67% median usage, and was well-tolerated, maintaining quality of life and neurocognitive function, according to the companies.

Novocure ( NVCR ) plans regulatory submission and peer-reviewed publication for phase 3 metis trial data, the companies said.

Price: 15.90, Change: -0.05, Percent Change: -0.31